Neurocognitive dysfunction and brain FDG-PET/CT findings in HIV-infected hemophilia patients and HIV-infected non-hemophilia patients.
Koubun ImaiSota KimuraYoko KiryuAki WatanabeEi KinaiShinichi OkaYoshimi KikuchiSatoshi KimuraMikiko OgataMisao TakanoRyogo MinamimotoMasatoshi HottaKota YokoyamaTomoyuki NoguchiKensuke KomatsuPublished in: PloS one (2020)
This single-institution cross-sectional study aimed to grasp the prevalence and features of neurocognitive dysfunction in HIV-infected hemophilia patients in Japan. We conducted neuropsychological tests and medical examinations in 56 HIV-infected hemophilia patients who received outpatient treatment at the AIDS Clinical Center, National Center for Global Health and Medicine. A total of 388 HIV-infected non-hemophilia patients who received outpatient treatment at the same institution were included as a control group. To investigate sites responsible for neurocognitive dysfunction in HIV-infected hemophilia patients using brain FDG-PET/CT scans, the accumulation of FDG in each brain region was compared. Approximately 50% of HIV-infected hemophilia patients had neurocognitive dysfunction. The prevalence of asymptomatic neurocognitive impairment was high (34%). Neurocognitive dysfunction was associated with educational level in HIV-infected hemophilia patients. In the symptomatic group, hemophilic arthropathy and history of cerebrovascular disorders were associated with neurocognitive dysfunction. Left temporal lobe function was reduced in the symptomatic group.
Keyphrases
- hiv infected
- end stage renal disease
- antiretroviral therapy
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- oxidative stress
- healthcare
- prognostic factors
- patient reported outcomes
- magnetic resonance imaging
- human immunodeficiency virus
- public health
- hepatitis c virus
- quality improvement
- smoking cessation
- patient reported
- contrast enhanced